Navigation Links
Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
Date:12/13/2011

THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm '209 study evaluating the safety and efficacy of Nplate in adults with primary immune thrombocytopenia (ITP) demonstrated that Nplate induced a rapid platelet response in adult ITP patients with low platelet counts or bleeding symptoms and maintained a consistent safety profile (Abstract No. 3279).

In the study, incidence and type of adverse events (AEs) in patients treated with Nplate were consistent with those reported in previous studies. The most common side effects included headache, arthralgia and fatigue.

Approximately 90 percent of patients achieved each of the platelet response definitions, regardless of splenectomy status. Median time to response was one to two weeks. Over the course of the study, a doubling of the platelet count to greater than or equal to 50,000 platelets per microliter was achieved by 91 percent of patients who received Nplate. A platelet count increase of greater than or equal to 20,000 platelets per microliter from baseline was achieved by 93 percent of patients who received Nplate.

"We are very pleased to present the final results from the largest prospective study of Nplate in adult patients with primary ITP, which highlight Nplate's ability to successfully treat these patients," said Sean E. Harper, M.D., senior vice president of Global Development and chief medical officer at Amgen. "Additional data presented at the meeting in other disease states help further elucidate the safety and efficacy profile of Nplate. Collectively, these data help
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
3. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
4. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
5. Amgen Announces 2011 Fourth Quarter Dividend
6. Amgen to Present at the UBS Global Life Sciences Conference
7. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
8. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
9. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
11. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... Mass. (PRWEB) March 03, 2015 Cambridge ... by Semantic Web technology, today announced that it has ... Companies That Matter in Knowledge Management.’ , To ... group of colleagues, analysts and system integrators who identify ... delivery of the right information to the right people ...
(Date:3/3/2015)... March 3, 2015 Elsevier,s ... for implementing competency-based training to comply with new CMS ... is offering a new crosswalk tool to ... competency-based training for direct service workers as a means ... Services (CMS) regulations. CMS amended the regulations, ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer ... researcher and founding partner of Criogenix SA de CV ... professors who will teach the “Diplomat in Cell Therapy ... is a private company registered in the National Record ... (RENIECYT). , Camacho Alcocer will teach two-day, interactive training ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... developed a novel mouse model mimicking human preterm labor have ... it to stop the problem.   (Logo: ... online the week of Oct. 24 by PNAS ... researchers report their findings may lead to new strategies for ...
... Inc. ("DLVR") - a privately-held biotechnology company currently ... proprietary high density lipoprotein-like nanoparticle -announced today that ... bringing the total raised to $2 million in ... University Health Network (UHN) and the Ontario Institute ...
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
Cached Biology Technology:Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 2Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 3DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... N.J. - The inaugural Global Conference on Systems ... in Washington, DC, focuses on the convergence of complex ... The goal of the ... around targeted complex systems, examined by domain, each successive ...
... to rise scientists are presented with the complex challenge ... paper published in Insect Conservation and Diversity , ... challenge. Twentieth-Century global warming of approximately 0.6˚C has ... challenge facing ecologists and evolutionary biologists is to predict ...
... A major obstacle to HIV research is the virus,s ... traditional tools, like the humble lab mouse, can deliver only ... Central,s open access Journal of Biology have made ... that has key features of HIV infection without being infected ...
Cached Biology News:First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2How can scientists measure evolutionary responses to climate change? 2A reductionist approach to HIV research 2
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: